Request Sample Inquiry
Immuno-oncology Clinical Trials Market

Immuno-Oncology Clinical Trials Market

Immuno-Oncology Clinical Trials Market - Global Industry Assessment & Forecast

img
Healthcare
Number Of Pages # Pages:

150

Base Year:

2022

Date

Sep - 2023

Format:

PDF XLS PPT

Report Code:

VMR-2267

Segments Covered
  • By Phase By Phase Phase I, Phase 2, Phase 3, Phase 4
  • By Design By Design Interventional Trials, Observational Trials, Expanded Access Trials
  • By Indication By Indication Solid Tumors, Hematological Cancer, Other Indications
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 5.8 Billion
Revenue 2030Revenue 2030: USD 18.1 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 15.3%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Immuno-Oncology Clinical Trials Market - Segment Analysis
    1. Overview
    2. Global Immuno-Oncology Clinical Trials Market, 2016 - 2028 (USD Million)
    3. Global Immuno-Oncology Clinical Trials Market - by Phase
      1. By Phase I
      2. By Phase 2
      3. By Phase 3
      4. By Phase 4
    4. Global Immuno-Oncology Clinical Trials Market - by Design
      1. By Interventional Trials
      2. By Observational Trials
      3. By Expanded Access Trials
    5. Global Immuno-Oncology Clinical Trials Market - by Indication
      1. By Solid Tumors
      2. By Hematological Cancer
      3. By Other Indications
    6. Global Immuno-Oncology Clinical Trials Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    7. Market comparative analysis
  4. North America Immuno-Oncology Clinical Trials Market - Segment Analysis
    1. Overview
    2. North America Immuno-Oncology Clinical Trials Market, 2016 - 2028 (USD Million)
    3. North America Immuno-Oncology Clinical Trials Market, by Phase
      1. By Phase I
      2. By Phase 2
      3. By Phase 3
      4. By Phase 4
    4. North America Immuno-Oncology Clinical Trials Market, by Design
      1. By Interventional Trials
      2. By Observational Trials
      3. By Expanded Access Trials
    5. North America Immuno-Oncology Clinical Trials Market, by Indication
      1. By Solid Tumors
      2. By Hematological Cancer
      3. By Other Indications
    6. North America Immuno-Oncology Clinical Trials Market, by Country
      1. U.S.
        1. U.S. Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. U.S. Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. U.S. Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      2. Canada
        1. Canada Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Canada Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Canada Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      3. Mexico
        1. Mexico Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Mexico Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Mexico Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
  5. Europe Immuno-Oncology Clinical Trials Market - Segment Analysis
    1. Overview
    2. Europe Immuno-Oncology Clinical Trials Market, 2016 - 2028 (USD Million)
    3. Europe Immuno-Oncology Clinical Trials Market, by Phase
      1. By Phase I
      2. By Phase 2
      3. By Phase 3
      4. By Phase 4
    4. Europe Immuno-Oncology Clinical Trials Market, by Design
      1. By Interventional Trials
      2. By Observational Trials
      3. By Expanded Access Trials
    5. Europe Immuno-Oncology Clinical Trials Market, by Indication
      1. By Solid Tumors
      2. By Hematological Cancer
      3. By Other Indications
    6. Europe Immuno-Oncology Clinical Trials Market, by Country
      1. Germany
        1. Germany Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Germany Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Germany Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      2. UK
        1. UK Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. UK Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. UK Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      3. France
        1. France Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. France Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. France Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      4. Spain
        1. Spain Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Spain Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Spain Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      5. Italy
        1. Italy Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Italy Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Italy Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      6. BENELUX
        1. BENELUX Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. BENELUX Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. BENELUX Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      7. Rest of Europe
        1. Rest Of Europe Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Rest Of Europe Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Rest Of Europe Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
  6. Asia Pacific Immuno-Oncology Clinical Trials Market - Segment Analysis
    1. Overview
    2. Asia Pacific Immuno-Oncology Clinical Trials Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Immuno-Oncology Clinical Trials Market, by Phase
      1. By Phase I
      2. By Phase 2
      3. By Phase 3
      4. By Phase 4
    4. Asia Pacific Immuno-Oncology Clinical Trials Market, by Design
      1. By Interventional Trials
      2. By Observational Trials
      3. By Expanded Access Trials
    5. Asia Pacific Immuno-Oncology Clinical Trials Market, by Indication
      1. By Solid Tumors
      2. By Hematological Cancer
      3. By Other Indications
    6. Asia Pacific Immuno-Oncology Clinical Trials Market, by Country
      1. China
        1. China Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. China Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. China Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      2. Japan
        1. Japan Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Japan Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Japan Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      3. India
        1. India Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. India Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. India Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      4. South Korea
        1. South Korea Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. South Korea Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. South Korea Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      5. South East Asia
        1. South East Asia Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. South East Asia Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. South East Asia Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Rest of Asia Pacific Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Rest of Asia Pacific Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
  7. Latin America Immuno-Oncology Clinical Trials Market - Segment Analysis
    1. Overview
    2. Latin America Immuno-Oncology Clinical Trials Market, 2016 - 2028 (USD Million)
    3. Latin America Immuno-Oncology Clinical Trials Market, by Phase
      1. By Phase I
      2. By Phase 2
      3. By Phase 3
      4. By Phase 4
    4. Latin America Immuno-Oncology Clinical Trials Market, by Design
      1. By Interventional Trials
      2. By Observational Trials
      3. By Expanded Access Trials
    5. Latin America Immuno-Oncology Clinical Trials Market, by Indication
      1. By Solid Tumors
      2. By Hematological Cancer
      3. By Other Indications
    6. Latin America Immuno-Oncology Clinical Trials Market, by Country
      1. Brazil
        1. Brazil Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Brazil Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Brazil Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      2. Argentina
        1. Argentina Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Argentina Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Argentina Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      3. Rest of Latin America
        1. Rest of Latin America Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Rest of Latin America Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Rest of Latin America Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
  8. Middle East & Africa Immuno-Oncology Clinical Trials Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Immuno-Oncology Clinical Trials Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Immuno-Oncology Clinical Trials Market, by Phase
      1. By Phase I
      2. By Phase 2
      3. By Phase 3
      4. By Phase 4
    4. Middle East & Africa Immuno-Oncology Clinical Trials Market, by Design
      1. By Interventional Trials
      2. By Observational Trials
      3. By Expanded Access Trials
    5. Middle East & Africa Immuno-Oncology Clinical Trials Market, by Indication
      1. By Solid Tumors
      2. By Hematological Cancer
      3. By Other Indications
    6. Middle East & Africa Immuno-Oncology Clinical Trials Market, by Country
      1. GCC Countries
        1. GCC Countries Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. GCC Countries Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. GCC Countries Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      2. South Africa
        1. South Africa Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. South Africa Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. South Africa Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Immuno-Oncology Clinical Trials Market, By Phase
          1. By Phase I
          2. By Phase 2
          3. By Phase 3
          4. By Phase 4
        2. Rest of Middle East & Africa Immuno-Oncology Clinical Trials Market, By Design
          1. By Interventional Trials
          2. By Observational Trials
          3. By Expanded Access Trials
        3. Rest of Middle East & Africa Immuno-Oncology Clinical Trials Market, By Indication
          1. By Solid Tumors
          2. By Hematological Cancer
          3. By Other Indications
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. ICON PLC (Ireland)
    2. IQVIA Holdings Inc. (U.S.)
    3. Covance (U.S.)
    4. BioNTech (Germany)
    5. IO Biotech Medical (Denmark)
    6. Medpace (U.S.)
    7. Novartis (Switzerland)
    8. Exscientia (UK)
    9. Syneous Health (U.S.)
    10. AstraZeneca (UK)
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 06-Sep-2023
Immuno-Oncology Clinical Trials Market to Reach Valuation of USD 18.1 Billion by 2030 – Growth in the Usage of Technology Such as Gene Editing, Next-Generation Sequencing, and Cellular Immunotherapy Drive the Market
FAQ
Frequently Asked Question

  • The global Immuno-Oncology Clinical Trials valued at USD 5.8 Billion in 2022 and is expected to reach USD 18.1 Billion in 2030 growing at a CAGR of 15.3%.

  • The prominent players in the market are ICON PLC (Ireland), IQVIA Holdings Inc. (U.S.), Covance (U.S.), BioNTech (Germany), IO Biotech Medical (Denmark), Medpace (U.S.), Novartis (Switzerland), Exscientia (UK), Syneous Health (U.S.), AstraZeneca (UK).

  • The market is project to grow at a CAGR of 15.3% between 2023 and 2030.

  • The driving factors of the Immuno-Oncology Clinical Trials include

    • Changes in lifestyle brought on by urbanization

  • North America was the leading regional segment of the Immuno-Oncology Clinical Trials in 2022.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy